962MO A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells (myDC) in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma

Activiteit: Talk or presentation at a conference

Periode17 sep 2021
EvenementstitelESMO Congress 2021
EvenementstypeConference
LocatieParis, France
Mate van erkenningInternational